Facilitating Access to PrEP

Jim Rooney

Gilead Sciences

IAPAC

London Jun 12 2012

Facilitating Access to PrEP

- Regulatory activities
- How will PrEP be made available in a clinical setting?
- Support for ongoing research
- Educational support
- Access

Regulatory activity

- Gilead in discussion with regulatory authorities in various countries regarding an indication for PrEP for Truvada (FTC/TDF).
- sNDA for Viread/Truvada for PrEP filed with the FDA Dec 2011.
  - This filing included data from iPrEx, Partners PrEP, TDF2, and the CDC US MSM study
  - FDA advisory committee meeting held May 10 2012; vote for approval
  - Decision expected by Sept 2012
- Discussions have been ongoing with the EMA in Europe but specific plans for filing not yet finalized
- Plans in place to file in Africa, Latin America, and Asia following FDA review

What a PrEP Indication Could Look Like

- **Pre-exposure prophylaxis of HIV Acquisition**
  - TRUVADA is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk
  - The following points must be considered when prescribing TRUVADA for pre-exposure prophylaxis:
    - This indication is based on studies in adults at high risk for sexually acquired HIV-1 infection
    - TRUVADA should only be used as part of a comprehensive prevention strategy because Truvada is not always effective in preventing the acquisition of HIV-1
    - All patients should be counseled to strictly adhere to their TRUVADA dosing schedule because the effectiveness of Truvada in reducing the risk of acquiring HIV-1 is strongly correlated with adherence and detectable drug levels

What a PrEP Indication Could Look Like

- Patients taking TRUVADA for PrEP should have a documented negative HIV test prior to initiating and routinely while taking Truvada for PrEP
  - HIV-infected patients taking Truvada must take Truvada with other antiretroviral agents to fully suppress virus replication and avoid the development of resistance

How will PrEP be made available in clinical practice?

- Drug will be the same as for HIV treatment (Truvada (FTC/TDF) and generic versions)
- Guidance could be normative, regulatory (by labeling), or both. Process may vary by country.
  - CDC has issued draft guidance for PrEP for high risk MSM in US based upon the iPrEx study; guidance to be revised to include data from Partners PrEP and TDF2
  - Guidelines being drafted by other groups (UK, France, EMA, WHO)
- Access to medication remains to be determined at the local level (same sites as for HIV treatment or other venues??) but Gilead Access Program will support both treatment and prevention. PEPFAR, Global Fund, WHO interested but decisions regarding the use of PrEP not yet established

Challenges for Regulators, the Community and Gilead

- Intervention may be less effective (or more effective) in real world vs. clinical trial setting (remains to be evaluated in demonstration projects)
- Potential for behavioral impact (disinhibition)
- Risk of resistance development in HIV+ individuals
- Risk of hepatic flares in HBV-infected individuals
- High cost relative to other prevention interventions; potential reimbursement barriers?
- Challenge of delivering appropriate education to healthcare providers and target populations
- Need to ensure no impact on ease of access to medication for HIV+ individuals

PrEP: Ongoing and Planned Phase 3B/4 Research, Including Demonstration Projects

- Phase 3 studies are continuing to evaluate PrEP in various demographic groups
- Gilead is committed to post-marketing demonstration studies in the U.S. and globally
- Collaborators: ANRS, CDC, FHI, MRC, NIAID (DAIDS), NICHD (ATN), BMGF, U. Illinois, U. Washington, UCSF, UCSD, UCLA, SFDPH, LADPH

Population	Studies	Participants
MSM	**14**	**12,980**
Heterosexual Men & Women Serodiscordant Couples	**8**	**19,500**
Total	**22**	**32,480**

ANRS = French National Agency for AIDS Research; MRC = Medical Research Council (UK); NIAID = National Institute of Allergy and Infectious Diseases; DAIDS = Division of AIDS; NICHD = National Institute of Child Health and Human Development; ATN = Adolescent Trials Network

PrEP: Phase 3B/4 Research and Demonstration Projects in MSM

Study	N	Duration	Location
Ongoing Phase 3 Studies			
IPERGAY (peri-coital)	1900	24 months	France, Canada
Demonstration Projects and Open-Label Extensions (planned and ongoing)			
iPrEx OLE (ongoing)	1500	72 weeks	U.S., Peru, Ecuador, Brazil, Thailand, South Africa
DAIDS PrEP MSM Demo	500	12 months	U.S.
CDC PrEP MSM Demo	1200	12 months	U.S.
PROUD	5000	12 months on tx, 12 month follow-up	U.K.
Project PrEPare 110 (Adolescents 18-22)	200	48 weeks	U.S.
Project PrEPare 113 (Adolescents 15-17)	100	48 weeks	U.S.
Kenya PrEP	160	12 months	Kenya
ALERT	600	1 year after enrollment of last subject	U.S.
Los Angeles PATH (Men of Color)	600	48 weeks	U.S.
NYC PrEP	200	12 months	U.S.
Rio PrEP (FTC/TDF +/- RAL; peri-coital)	65	12 months	Brazil
HPTN 073 (African American MSM)	900	12 months	U.S.
Fenway	55	6 months	U.S.
TOTAL: 14	**12,980**		

Phase 3B/4 Research and Demonstration Projects in Heterosexual Women and Men

Study	N	Duration	Location
Ongoing Phase 3 Studies			
Partners PrEP (discordant couples)	4758 couples	12 month extension	Kenya, Uganda
MTN 003/VOICE (women)	5029	36 months	Uganda, South Africa, Zimbabwe
CDC Bangkok TDF Study (men and women IDUs)	2413	48 months	Thailand
Demonstration Projects and Open-Label Extensions (planned and ongoing)			
TDF2 Open-Label Extension (men and women)	900	12 months	Botswana
CHAMPS (men and women 14-18 years)	100	12 months	South Africa
MTN 018/CHOICE (women)	4300	12 months	Uganda, South Africa, Zimbabwe
Partners PrEP Demo (discordant couples)	1000 couples	24 months	Kenya, Uganda
Gilead PrEP Registry (men and women)	Up to 1000	36 months	U.S.
TOTAL: 8	**19,500**		

Support for ongoing research

- Phase 1 and 2 studies of alternative dosing strategies and regimens and populations
  - Intermittent dosing
    - HPTN 066, 067 (ADAPT)
  - Alternative regimens
    - HPTN 069 (miraviroc+/- TDF or FTC)
  - Alternative populations
    - Adolescent studies in young MSM ages 16-22 (ATN)
- PrEPception??!!
- Support for microbicide gel research; vaginal, rectal, new formulations and patient populations, safety and efficacy trials
- New drugs; new prodrug of tenofovir GS 7340; new prevention specific ARVs?

Education and Outreach

- Gilead has convened stakeholder meetings in multiple US cities to get feedback on the potential use of PrEP in the US
- Initial meetings focused on MSM but subsequent meetings have included discussion of PrEP in heterosexuals as well
- Gilead is developing educational materials on PrEP
  - CME programs, website, info for healthcare providers and potential PrEP recipients
  - Will focus on approved labeling and CDC guidelines in US
  - Education via third party. No direct Gilead promotion
  - Risk Evaluation and Mitigation Strategy (REMS) will be part of the FDA submission and will focus on HIV testing and use of PrEP as part of a comprehensive package of prevention measures

Thank you